Facts about GLP-1/GIP agonist- Tirzepatide
GLP-1's have gotten a bad reputation due to abuse of the medication. When treatment is not properly guided with nutritional and training support- the results can be devastating with an inability to ever stop the…
Content is educational only and does not diagnose, treat, or prescribe. Individual results vary. Prescriptions are never guaranteed. Discuss personal questions with a licensed clinician.
GLP-1's have gotten a bad reputation due to abuse of the medication. When treatment is not properly guided with nutritional and training support- the results can be devastating with an inability to ever stop the medication. However, the medication is powerful at treating and curing so many issues. We have had patients stop all blood pressure medications and statins. Below is a concise, evidence-based table of medical benefits for dual GLP-1/GIP receptor agonists (currently tirzepatide — Mounjaro® / Zepbound®). Benefits are grouped by FDA-approved vs. strong off-label / emerging uses. All data from phase 3 RCTs (SURPASS, SURMOUNT) and 2023–2025 meta-analyses.
NAFLD / MASH (Metabolic Dysfunction-Associated Steatohepatitis)
Heart Failure with Preserved Ejection Fraction (HFpEF) + Obesity
Preclinical + observational (Alzheimer’s & Dementia 2024)
Educational only — not medical advice. Plans are personalized after clinical evaluation; prescriptions are never guaranteed.